Zim Laboratories share news and announcements
NSE: ZIMLABBSE: 541400Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹132.12.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹677 Cr1,933rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 183.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 2.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 1.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,16,71445.7% delivered
Zim Laboratories analyst meets
65 filed, newest first. Page 1 of 2.
Aug 2026
4 Aug · Analysts
Jun 2026
30 Jun · Analysts
30 Jun · Analysts
15 Jun · Analysts
13 Jun · Analysts
May 2026
13 May · Analysts
Mar 2026
16 Mar · Analysts
Feb 2026
6 Feb · Analysts
Dec 2025
13 Dec · Analysts
8 Dec · Analysts
Nov 2025
10 Nov · Analysts
Aug 2025
7 Aug · Analysts
6 Aug · Analysts
Jun 2025
17 Jun · Analysts
May 2025
29 May · Analysts
14 May · Analysts
Feb 2025
28 Feb · Analysts
19 Feb · Analysts
13 Feb · Analysts
Dec 2024
2 Dec · Analysts
Nov 2024
25 Nov · Analysts
19 Nov · Analysts
5 Nov · Analysts
Sep 2024
18 Sep · Analysts
Aug 2024
26 Aug · Analysts
6 Aug · Analysts
5 Aug · Analysts
Jun 2024
14 Jun · Analysts
May 2024
8 May · Analysts
Mar 2024
5 Mar · Analysts
5 Mar · Analysts
Feb 2024
16 Feb · Analysts
15 Feb · Analysts
12 Feb · Analysts
Jan 2024
23 Jan · Analysts
Dec 2023
6 Dec · Analysts
6 Dec · Analysts
4 Dec · Analysts
Nov 2023
25 Nov · Analysts
22 Nov · Analysts
21 Nov · Analysts
3 Nov · Analysts
Sep 2023
18 Sep · Analysts
15 Sep · Analysts